Tanaka Toshihiro, Kuroki Motomu, Hamada Hirofumi, Kato Kazunori, Kinugasa Tetsushi, Shibaguchi Hirotomo, Zhao Jun, Kuroki Masahide
Department of Biochemistry, Faculty of Medicine, Fukuoka University, Sapporo Medical University, Japan.
Anticancer Res. 2007 Nov-Dec;27(6A):3679-84.
Gene therapy has the potential to provide highly selective, curative cancer treatments without inducing systemic toxicity. Adenoviral vectors have been extensively used for cancer gene therapy because of their relatively high efficacy of gene transfer. However, gene transduction to cancer cells is limited by the necessity of using adenoviral type 5 vectors. This is because these vectors have a low transduction efficiency due to weak expression of the adenovirus receptor, coxsackie-adenovirus receptor (CAR), on cancer cells. Moreover, there may be side-effects to the treatment as normal cells also express CAR. In order to eradicate cancer cells without side-effects, the development of a targeting-vector is therefore crucial. In this review, the recent targeting strategies of adenoviral vectors for cancer gene therapy are summarized.
基因治疗有潜力提供高度选择性的、治愈性的癌症治疗方法，且不会引发全身毒性。腺病毒载体因其相对较高的基因转移效率，已被广泛用于癌症基因治疗。然而，由于需要使用5型腺病毒载体，癌细胞的基因转导受到限制。这是因为这些载体在癌细胞上的转导效率较低，原因是腺病毒受体柯萨奇病毒-腺病毒受体（CAR）的表达较弱。此外，由于正常细胞也表达CAR，治疗可能会有副作用。因此，为了在无副作用的情况下根除癌细胞，开发靶向载体至关重要。在这篇综述中，总结了腺病毒载体用于癌症基因治疗的最新靶向策略。
